Eli Lilly EPS - Earnings per Share 2010-2022 | LLY

Eli Lilly annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Eli Lilly EPS for the quarter ending March 31, 2022 was $2.10, a 40.94% increase year-over-year.
  • Eli Lilly EPS for the twelve months ending March 31, 2022 was $6.73, a 0.75% increase year-over-year.
  • Eli Lilly 2021 annual EPS was $6.12, a 9.87% decline from 2020.
  • Eli Lilly 2020 annual EPS was $6.79, a 23.62% decline from 2019.
  • Eli Lilly 2019 annual EPS was $8.89, a 184.03% increase from 2018.
Eli Lilly Annual EPS
2021 $6.12
2020 $6.79
2019 $8.89
2018 $3.13
2017 $-0.19
2016 $2.58
2015 $2.26
2014 $2.23
2013 $4.32
2012 $3.66
2011 $3.90
2010 $4.58
2009 $3.94
Eli Lilly Quarterly EPS
2022-03-31 $2.10
2021-12-31 $1.88
2021-09-30 $1.22
2021-06-30 $1.53
2021-03-31 $1.49
2020-12-31 $2.31
2020-09-30 $1.33
2020-06-30 $1.55
2020-03-31 $1.60
2019-12-31 $1.77
2019-09-30 $1.37
2019-06-30 $1.44
2019-03-31 $4.31
2018-12-31 $1.10
2018-09-30 $1.12
2018-06-30 $-0.25
2018-03-31 $1.16
2017-12-31 $-1.57
2017-09-30 $0.53
2017-06-30 $0.95
2017-03-31 $-0.10
2016-12-31 $0.73
2016-09-30 $0.73
2016-06-30 $0.71
2016-03-31 $0.41
2015-12-31 $0.45
2015-09-30 $0.75
2015-06-30 $0.56
2015-03-31 $0.50
2014-12-31 $0.40
2014-09-30 $0.47
2014-06-30 $0.68
2014-03-31 $0.68
2013-12-31 $0.68
2013-09-30 $1.11
2013-06-30 $1.11
2013-03-31 $1.42
2012-12-31 $0.74
2012-09-30 $1.18
2012-06-30 $0.83
2012-03-31 $0.91
2011-12-31 $0.77
2011-09-30 $1.11
2011-06-30 $1.07
2011-03-31 $0.95
2010-12-31 $1.05
2010-09-30 $1.18
2010-06-30 $1.22
2010-03-31 $1.13
2009-12-31 $0.82
2009-09-30 $0.86
2009-06-30 $1.06
2009-03-31 $1.20
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.134B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
Novartis AG (NVS) Switzerland $181.123B 13.18
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27